Two recent studies offer fresh insights into how antidepressants, often prescribed to help manage mood and anxiety, are prescribed in Huntington’s disease (HD) and might also influence cognitive decline. One study zooms in on medication use in HD, while the other takes a broader look at dementia and antidepressants. Together, they reveal a complex and evolving map of treatment decisions.
In the early stages, people with HD take an average of 2.5 medications. But as the disease advances, that number more than doubles to 5.2. This really highlights just how much a person’s medical needs change as HD progresses.
So, what medications are people taking? The study found that antipsychotics (used to manage movement symptoms and psychiatric issues), selective serotonin reuptake inhibitors (SSRIs, a common class of antidepressants), and painkillers (for chronic discomfort associated with HD) top the list.
Surprising Factors
But here’s where things get really interesting—prescription patterns vary based on factors like disease stage, gender, and location. For instance, men with HD are more likely to be prescribed antipsychotics, while women tend to use more antidepressants and painkillers.
The geographical divide is equally fascinating: In North America, SSRIs are the go-to choice, whereas in Europe, doctors are more likely to prescribe antipsychotics.
Why? It could be differences in treatment guidelines, cultural attitudes toward medications, or even drug cost and availability. Whatever the reason, this variation suggests that medication choices might be influenced by more than just individual patient needs.
What’s important here is that this study actually looked at what medications people were using, not just what their doctors recommended. So this gives us a much more realistic picture of what’s actually happening. This is valuable because it gives us a peek into the real world, the lived experience of these folks who are dealing with HD on a day-to-day basis.
Treatment Shift
Another crucial takeaway from the study is how medication use shifts over time. Early on, doctors may focus on medications that aim to manage mood and anxiety. But as involuntary movements and challenging behaviors become more prominent, treatment shifts toward managing these more disruptive symptoms.
This shift is particularly evident in the use of antipsychotics, which increase significantly as HD progresses.
Meanwhile, people who develop the rare form of juvenile HD show different medication patterns altogether, often requiring more treatments for aggression and irritability rather than for movement symptoms.
These findings highlight the need for personalized treatment approaches that consider unique disease trajectories and needs of different patient groups, particularly for those with juvenile HD.
Antidepressant Use in People with Dementia
A second study steps back from HD specifically and looks at a broader question: Do antidepressants influence cognitive decline in people with dementia? Antidepressants are often prescribed for people with dementia to help manage the psychological symptoms that come with the disease, like anxiety and depression.
Using data from the Swedish Registry for Cognitive Dementia Disorders, researchers examined whether certain antidepressants might actually accelerate cognitive deterioration. And the findings are raising eyebrows.
Among people with dementia, those taking antidepressants—especially SSRIs—experienced faster cognitive decline. The effect was particularly pronounced in individuals with more severe dementia at the study’s start.
However, it’s critical to note that some other studies have shown conflicting results, which just goes to show how complex this issue is. These findings add layers of complexity for the decision-making process for doctors and patients around the use of these medications, particularly for the most vulnerable groups of people with severe dementia.
More Medicine, Faster Decline?
Interestingly, they also suggest there is a dose-response relationship—meaning that higher doses of SSRIs were linked to an even greater rate of cognitive decline.
Medications like sertraline, citalopram, and escitalopram—widely used SSRIs—were the most strongly associated with cognitive decline. This raises important questions: Are these medications helping more than they’re harming? Should doctors rethink how and when they prescribe them to people with dementia?
Another intriguing twist? The study found that men experienced a steeper cognitive decline on antidepressants compared to women, despite the fact that women are more likely to be prescribed these medications. Additionally, people who were not taking anti-anxiety or sleep medications alongside their antidepressants showed a more pronounced decline. Could other medications be offering some kind of protective effect, or is this just a coincidence? The answers remain unclear, highlighting the limitations of this study and the need for further research.
Things to Keep In Mind
There are some critical caveats for the study that links accelerated dementia to antidepressant use that people need to keep in mind, because this study isn’t a one-to-one comparator for people from HD families.
First, depression itself is associated with dementia and cognitive impairment, so we can’t really tease apart the chicken-and-egg problem here. The associations between antidepressant use and cognitive decline could be due to the underlying psychiatric condition rather than the drug itself. In other words, people may be prescribed antidepressants because their symptoms are worse or progressing more rapidly – the underlying cause of decline is the brain disease, not the drug. Although the researchers tried to account for this, it’s not something we can entirely rule out.
Second, dementia severity could itself be contributing to cognitive decline, making it difficult to conclusively say the results they saw were because of the antidepressants. The relationship between antidepressant use and dementia severity is complicated. From the Enroll-HD data described here, we know that treatment and medication use evolves as HD progresses, which should likely be the case for other diseases as well, like dementia.
Third, different forms of dementia have very different biological causes, like Alzheimer’s, Lewy body dementia, or frontotemporal dementia. But this study grouped these various types of dementia together. This could be masking some of the disease-specific effects that may be at play between the effects of antidepressants and these specific types of dementia. To add to this, HD is also a unique disease which likely has its own individual effects with specific medications. For that reason, it’s important to assess medication effects at the individual disease and patient level, rather than drawing conclusions broadly across a group of diseases.
Lastly, and perhaps most importantly, this study looked at association, not causation. These types of study designs that aren’t testing medications in a blinded clinical trial have major limitations. They just don’t have the power or rigor to draw black-and-white conclusions about what is happening biologically. However, they are good at making associations between events, like the use of antidepressants and cognitive decline, that can be examined in more detail in future studies.
Don’t Toss Your Meds!
Both studies highlight the delicate balancing act of prescribing medications for neurodegenerative diseases based on the individual. For people with HD and other forms of dementia, medications can provide crucial relief from psychiatric and motor symptoms.
A critical takeaway is that these recent findings don’t mean antidepressants should be abandoned for HD! Rather, they underscore the need for a thoughtful, individualized approach through collaborative relationships between clinicians, patients, and caregivers. Often people close to us know us better than we know ourselves, and this is particularly true for caregivers.
For many people with HD, the short-term risk from depression or challenging behaviours is huge – these are symptoms that can all too easily lead to injury, self-harm, and premature death. Balancing short-term and long-term risks, and the potential harms and benefits from treatment options, is a delicate business demanding full engagement between patients, their loved ones, and medical professionals.
Conversations between HD families and doctors should be open and honest, so that clinicians can remain vigilant, adjusting treatment plans based on the latest research and the evolving needs of each patient. This could also include helping people find access to non-drug treatments, like therapy, support groups, and lifestyle changes.
The Road Ahead
The studies discussed here are a reminder that medicine is never one-size-fits-all. Particularly for HD, medication use is incredibly common and just gets more frequent and more complicated as the disease progresses. Treatment patterns can be so different for various groups, which really highlights the need for open and honest dialog between patients and doctors to develop personalized care plans.
This work also highlights how much we still have to learn about the brain and the interplay between medications and neurodegeneration. More research is needed to untangle these complex relationships, but one thing is clear: Whether in HD or broader dementia care, the goal remains the same—to create a smoother, safer journey for those navigating these difficult conditions.
For now, patients and families should stay informed, ask questions, and work closely with their doctors to ensure that treatments align with their individual needs. Because when it comes to the brain’s roadmap, careful navigation is key to getting where we want to go.
Over the past year, HDBuzz has been evolving, growing, and delivering on its mission—bringing clear, accessible, and accurate Huntington’s disease (HD) research news to families and researchers around the world. From major clinical trial updates to scientific breakthroughs, we’ve been at the forefront, translating complex science into clear, understandable insights. But as HD research advances, so must we. Today, we’re launching our Spring Giving Campaign: “Hope in Full Bloom”—an opportunity for our community to come together and ensure that HDBuzz remains the trusted source for HD research news.
A Year of Growth and Impact
It’s been one year since HDBuzz transitioned to new leadership. In that time, we have:
Doubled article outputon critical HD research developments. If you feel like you’ve been seeing more HDBuzz content than ever before, you’re not imagining it! As the pace of HD research has accelerated, we’ve matched it. In past years, HDBuzz was churning out about 2 articles a month, and recently we’ve settled in to publishing about an article a week. But we’re not stopping there! HD researchers keep cranking out amazing science and clinical trial updates are on a roll, so we’re ramping up too! You may have noticed our Monday/Thursday publication schedule in March, which will be our new norm, so prep your inbox for HDBuzz emails twice a week moving forward.
Expanded our teamby bringing in new writers from top research institutions. As our output has grown, so has our writing team, offering readers perspectives from fresh voices within the HD research community. And we’re excited to expand this initiative too! We’re bringing back the HDBuzz Prize for Young Science Writers this summer, so stay tuned.
Launched new social media channels (Instagram,Bluesky)to reach more people in new ways. The way people read and receive information is evolving, so we’re meeting people where they are—on new social media platforms. This will help us bring you our same great content in a fresh way while reaching a broader audience across multiple platforms to keep the global community up to date on HD research breakthroughs.
Strengthened our funding model, raising over $23,000 through direct reader donations since October.Thank you! We’re still working toward financial independence and sustainability, but because of loyal readers and supporters, we’re headed there.
2025 is shaping up to be a pivotal year in HD research!
Major clinical trials are reaching key milestones. The second quarter of this year will bring long-awaited data from multiple trials testing potential disease-modifying treatments. This includes both uniQure and PTC Therapeutics, who are both expected to report critical results by the end of June. Families, advocates, and researchers around the world will be looking for trusted, clear, and independent analysis—the kind of reporting that HDBuzz specializes in.
The global HD community depends on accurate, unbiased information. With so much at stake, it’s critical that families have a source they can trust—one that cuts through jargon and provides clear, relevant updates.
The Challenge: Keeping HDBuzz Strong
While our impact is growing, so are the challenges of sustaining independent science journalism.
HDBuzz is funded entirely by donations from HD community organizations and readers. Unlike traditional media, we don’t sell ads or operate behind a paywall. We believe research news should be free to everyone, no matter their location or financial situation.
Importantly, HDBuzz has never accepted funding or support from drug companies. We love drug companies—we’re hoping they help us cure HD! But taking money from any organization dedicated to a particular therapy could give the impression of bias in our reporting, which we diligently aim to avoid.
Our goal is to raise $30,000 by May 27 to keep HDBuzz thriving, expand our reporting, and prepare for the biggest HD research updates of the year.
Here’s how you can help:
Make a donation today—whether it’s a one-time gift or a monthly contribution. Every dollar fuels HD research news that remains free for all.
Share our campaign with your network—on social media, in HD support groups, or with friends and family.
Stay engaged—follow our updates, comment on our posts, and help amplify trusted HD research news.
Follow us on social media and spread the word—like, share, and invite your friends and family to follow us too. We’re on Facebook,Instagram,LinkedIn, and Bluesky. Every new follower helps expand awareness and support for HD research.
What Your Support Makes Possible
$10/month helps us translate articles into multiple languages, reaching HD families worldwide.
$50 supports real-time reporting from major HD research conferences.
$200 funds an in-depth, expert-written article breaking down the latest scientific data.
If just 5% of our readers gave $20/month, we would be independently sustainable by the end of the year.
Join Us—Hope in Full Bloom for HD Research
Now is the time. With major trial results on the horizon, groundbreaking research happening now, and a growing community that relies on our reporting, we need your support more than ever.
Every donation, every share, and every engagement strengthens our ability to deliver trusted, timely, and independent HD research news.
March 2025 was packed with groundbreaking discoveries in Huntington’s disease (HD) research, and we’re here to bring you the biggest highlights! From the cutting-edge CRISPR delivery system RIDE, which could rewrite the playbook on gene editing, to major advances in drug development, biomarker breakthroughs, and fresh insights into HD biology, this month was a whirlwind of progress. Scientists are pushing the boundaries of what’s possible, inching closer to real solutions for HD families. March not only brought us scientific progress, but also community events, like HDYO’s International Young Adult Congress and Factor-H’s Gratitude Day, that raise awareness about HD, provide a platform of support, and bring the community together. If you missed any of the exciting updates, don’t worry—we’ve got you covered. Dive into our March recap and catch up on all the HD news you need to know!
CHDI
Every year CHDI hosts one of the largest HD research conferences. The 2025 HD Therapeutics Conference showcased significant advancements in research and potential therapies for HD. Over three days, more than 400 scientific experts from around the world convened to discuss clinical trial updates, genetic modifiers, and innovative technologies.
Day 1: Progress in Clinical Trials
The conference began with updates on therapeutic trials targeting huntingtin (HTT), the protein responsible for HD. Researchers shared data on ongoing efforts to reduce HTT levels safely, including small molecule drugs and gene therapies. Discussions also focused on refining clinical trial design, selecting meaningful biomarkers, and ensuring that future trials are better equipped to detect therapeutic benefits.
Day 2: Genetic Modifiers and Disease Progression
The second day explored genetic factors that influence when HD symptoms begin and how the disease progresses. Scientists presented findings from large-scale genetic studies identifying key modifiers that may delay disease onset, offering promising new therapeutic targets. Advances in understanding DNA repair pathways and their role in HD progression were also highlighted, providing new directions for potential treatments.
Day 3: New Technologies and Future Directions
The final day spotlighted cutting-edge technologies that could revolutionize HD research and treatment. Talks covered advances in gene editing, innovative drug delivery methods, and AI-driven approaches to analyzing HD progression. Researchers emphasized the importance of collaboration and continued innovation to translate these discoveries into real-world therapies.
The conference reinforced the growing momentum in HD research, with scientists and industry partners working together to turn breakthroughs into meaningful treatments for families affected by HD.
Wake up call: Sleep is impacted before Huntington’s disease symptoms appear
A recent study, highlighted during Sleep Awareness Week, reveals that sleep disturbances can occur in individuals carrying the HD gene up to 15 years before the onset of other symptoms. Researchers observed that those less than 15 years from predicted symptom onset experienced fragmented sleep and increased nighttime wakefulness, while those more than 15 years away may not show significant sleep issues. These findings suggest that early sleep disruptions may contribute to thinking and mood impairments associated with HD, highlighting the potential of sleep-focused interventions to improve quality of life and possibly slow disease progression.
Listening for Whispers: How a Tiny Protein Could Transform HD Research
A recent 14-year longitudinal study has demonstrated that neurofilament light (NfL), a protein released by damaged brain cells, can serve as an early indicator of HD progression. Elevated NfL levels were detected in individuals carrying the HD gene many years before the onset of symptoms, correlating with disease advancement. This finding suggests that monitoring NfL through simple blood tests could revolutionize HD research by predicting symptom onset, enhancing clinical trial design, and enabling earlier therapeutic interventions to potentially slow or halt disease progression.
The Huntington’s Disease Youth Organization’s World Congress: Supporting Young People Affected by HD
The Huntington’s Disease Youth Organization (HDYO) supports, educates, and empowers young people affected by HD. HDYO’s recent biennial International Young Adult Congress provided a unique space for connection and learning. At the 2025 Congress in Prague, attendees engaged in workshops, heard from leading researchers, and shared personal experiences, fostering a strong sense of community.
HDBuzz gave two presentations, firstly setting the stage with HD research terminology 101, then diving into an overview of important research going on at the benchside and in the clinic. Key themes in other talks included mental health, genetic testing decisions, and navigating family dynamics, with experts offering guidance tailored to young people facing HD. The event underscored the importance of youth involvement in research, advocacy, and peer support, reinforcing HDYO’s mission to empower the next generation of HD families.
Gratitude Day
Factor-H is a nonprofit dedicated to supporting HD families in Latin America, where extreme poverty and lack of resources make the disease even more devastating. This month, HDBuzz caught up with Factor-H founder, Dr. Ignacio Muñoz-Sanjuán, in an interview that details the unique problems that people with HD there face, and how they help and support these vulnerable families.
The organization provides humanitarian aid, medical care, housing improvements, education, caregiver training, and legal advocacy to some of the most vulnerable HD communities in Venezuela, Peru, and Colombia. These same communities played a crucial role in the discovery of the HD gene in 1993, yet many still lack basic necessities. Factor-H also works to combat stigma, educate the public, and advocate for sustainable, long-term support.
A key initiative is Gratitude Day, held this year on March 23rd, which honors HD families’ contributions to research while raising awareness of their ongoing struggles. The 2025 event included a live stream from Venezuela, candlelight vigils, and medical outreach, reinforcing the importance of global solidarity. Factor-H’s mission highlights the need for both immediate relief and systemic change, ensuring that hope and humanity—not just hardship—define the future for HD families.
Molecular Surgeons for Huntington’s Disease Catch a RIDE with CRISPR Advancements
A groundbreaking gene-editing technology called RIDE (Ribonucleoprotein Delivery) is showing promise for treating HD. RIDE uses CRISPR, a powerful tool to edit DNA, and delivers it precisely to targeted cells in the brain, overcoming key challenges like off-target effects and immune responses. Early tests in mice and monkeys have demonstrated that RIDE can effectively reduce harmful HTT protein levels in the brain, leading to improved behavior and motor function. This system offers lasting effects from a single injection and is designed to minimize the risks of unintended genetic changes. While still in early stages, RIDE’s targeted approach brings new hope for HD treatments, with the potential for broader applications in genetic diseases.
March was an exciting month for HD research, filled with groundbreaking discoveries, inspiring community events, and promising advancements toward better treatments. We hope you enjoyed this recap and feel as energized as we do about the increased pace of progress being made. Science is moving fast, and every step forward brings us closer to real treatments for HD families. Stay tuned to HDBuzz for the latest updates in HD research, and as always, thank you for being part of this journey with us!
Imagine a tiny, microscopic surgeon moving through the body, making precise genetic repairs exactly where they’re needed. That’s the vision behind a groundbreaking new gene-editing delivery system called RIDE—Ribonucleoprotein Delivery—recently featured in Nature Nanotechnology. This system offers a novel way to deliver CRISPR, a powerful gene-editing tool, to specific cells in the body. Researchers have tested RIDE in mice and monkeys, with promising results for diseases like Huntington’s disease (HD). Let’s dive into how this innovative system could shape the future of HD treatments.
CRISPR Challenges
CRISPR has revolutionized the way scientists approach genetic diseases, acting as a molecular “find and replace” tool for DNA. For HD, where an expanded CAG repeat in the huntingtin (HTT) gene leads to breakdown of brain cells, CRISPR could potentially correct or silence the faulty gene. However, several key challenges have stood in the way:
Off-Target Effects – CRISPR must be highly precise to avoid accidental edits in unintended parts of the genetic code.
Immune System Response – The body may recognize the CRISPR components as foreign invaders and attack them.
Targeted Delivery – The therapy must reach the right cells in the brain, specifically nerve cells in the very center of the brain that’s most affected in HD, without affecting other tissues.
RIDE aims to overcome these hurdles by packaging CRISPR into engineered particles that have been given brain-specific navigation systems that lets them go to specific cell types.
How RIDE Works
RIDE delivers CRISPR in the form of ribonucleoproteins , which are pre-formed complexes of the editing enzyme and guide RNA—think of this like the genetic navigation system that directs RIDE exactly where to go. The complex is packaged inside a virus-like particle, which acts as a protective car. These particles can be engineered with molecular tags, similar to putting a precise street address in your car’s navigation system, so that they target specific cells, ensuring precise delivery.
The key innovation of RIDE lies in its ability to be customized for different cell types. By modifying the outer shell of these nanoparticles with specific molecular tags, scientists can direct them toward desired cells, ensuring that the CRISPR machinery reaches the correct targets. This is a big leap forward for CRISPR-based gene editing.
To visualize the process, imagine a package being delivered. Current CRISPR approaches can make deliveries to the right neighborhood, but RIDE is a door-to-door service that drops the package at the exact address. RIDE’s customization allows the CRISPR machinery to be sent exactly where it’s needed, reducing off-target effects and improving efficiency.
Testing RIDE for HD
Researchers tested RIDE in mice that model HD, focusing on neurons in the striatum—the central brain region most affected by HD. The goal was to silence or edit the mutated HTT gene that causes HD to slow or stop disease progression.
The results were striking: treated mice showed a reduction in HTT protein levels and improved behavior compared to untreated HD mice, such as their movement control on obstacle courses. Importantly, the editing efficiency was much higher than what has been achieved with other delivery methods that don’t have a cellular navigation system, and there were fewer signs of unwanted genetic changes or immune responses.
Another promising aspect of RIDE is its potential to provide long-lasting effects. All the results in these mice were achieved with just a single injection of RIDE; they didn’t need to continuously administer the treatment. They monitored the mice for over 110 days (which is quite a long time in a mouse’s lifespan!), and the improvements persisted.
An important safety component of the RIDE system is that the gene-editing tools are delivered as an assembled complex rather than as genetic material. This means that it’s only around for a short time, long enough to do its job, before being quickly degraded by the cell’s natural processes—another big leap forward for this CRISPR-based gene editing approach. This reduces the risk of persistent off-target effects that could arise from prolonged CRISPR activity.
Beyond Mice
To really assess the potential of RIDE for treating HD in humans, the researchers needed to move beyond mice. That’s where the monkey studies come in. These studies help get a better understanding of how RIDE might behave in a system that’s more closely related to humans.
Safety was the top priority considering this treatment involves injecting something directly into the brain. They used MRI scans to look for any signs of brain damage after a RIDE injection, and they didn’t find any. They analyzed brain tissue samples and found that RIDE was in fact able to reduce levels of the non-expanded HD protein in the targeted areas. So they’re seeing consistent results in both mice and monkeys, which is a good sign.
The researchers also went a step further to confirm that RIDE could work in human cells. To do this, they used stem cells that they turned into neurons. These studies checked many of the boxes that suggested this technology is working: they were able to target and edit the HD gene and there were surprisingly minimal off-target effects. So they got the green light for RIDE in a human-based model as well.
What This Means for HD Families
While these results are promising, RIDE is still in early stages of development. Further studies in larger animals, and eventually human trials, will be necessary before this approach can be considered for clinical use.
However, this study is a major step forward in the field of gene therapy. It demonstrates that RIDE has the potential to be a safe, effective, and highly targeted method for delivering CRISPR-based drugs. And the researchers are already exploring ways to expand RIDE’s capabilities, including the potential to use systemic delivery.
Systemic delivery could mean scientists would be able to inject RIDE into the bloodstream and have it reach cells within the brain. This would be incredible, and a game-changer for HD and many other genetic diseases. Research breakthroughs around CRISPR are moving quickly—this technology has the potential to change the landscape of medicine as we know it.
Looking Ahead
RIDE represents an exciting step forward in the search for effective HD treatments. By combining the precision of CRISPR with an advanced delivery system that targets specific cell types and shuts off after editing, scientists are getting closer to making genetic therapies for HD a reality. And this team isn’t the only one working on this type of approach.
While we’re still in the early stages of this research, this breakthrough brings new hope to the HD community. This study offers a glimpse into a future where we might be able to treat genetic diseases, like HD, with unprecedented precision and effectiveness.
Stay tuned for more updates on how gene-editing technologies like RIDE continue to evolve and push the boundaries of what’s possible in HD research.
There are heroes who walk among us. In the Huntington’s disease (HD) community, some of those heroes are the leaders of Factor-H—a nonprofit organization dedicated to improving the lives of HD families in underserved communities by providing humanitarian aid, education, and advocacy. Huntington’s is an unrelentingly cruel disease that afflicts families with generation after generation of trauma, medical challenges, and overwhelming emotional, financial, and social burdens that can make even the simplest aspects of daily life a struggle.
What could make HD worse? Abject poverty so extreme that families are left utterly resourceless, living in tin-roofed huts with dirt floors without mattresses, electricity, or running water. This is the reality for some of the largest clusters of HD families in the world, located in South America—the same families that contributed to the research that discovered the gene that causes HD. Even still, every scientific advancement that the HD community hopes for and closely scrutinizes likely won’t make its way to these unimaginably vulnerable populations of people without help. That help is Factor-H.
This year, in honor of Gratitude Day—happening today, March 23rd—the HDBuzz editorial team is shining a light on the heroic work being done by Factor-H in an interview with Dr. Ignacio Muñoz-Sanjuán (aka Nacho), President and Founder of Factor-H. Here, we are joining in the spirit of the day, showing gratitude for all that they’re accomplishing for a community to which the global HD families owe so much, while helping to amplify Factor-H’s mission.
The Beginning
HDBuzz: Can you introduce yourself and tell us about your background in Huntington’s disease research and advocacy?
Nacho: I’m a neuroscientist with a specialty in Huntington’s disease. I worked at CHDI Foundation for 15 years as their Vice President for translational biology where my focus became very much concentrated on all aspects targeting huntingtin lowering and then circuit-related therapeutic development. Pretty much anything that related to advancing novel therapeutics for Huntington’s disease, I was responsible for on the biology side.
I came into the field of Huntington’s purely by serendipity. It so happened that one of the science directors of CHDI was a colleague of mine. And back in 2006, they were looking for a head of biology. So, she contacted me, I came down and I decided to venture into this new world of nonprofit foundations doing research. So that’s how I landed in Huntington’s disease.
On the advocacy side, it was a completely unplanned life trajectory. Soon after I started at CHDI, in 2008, I got people affiliated with the organization to come with me to Mexico City, because I had a friend who was the director of the Genomic Medicine Institute in Mexico. I was encouraging people in South America to participate in research studies. And a friend of mine told me, “Nacho, don’t you know the history of Venezuela? We’ve been asking people to participate in a lot of things and they don’t even have any food to eat.” I really didn’t know that aspect of the situation in Venezuela. So, it kind of got me thinking, okay, well, there’s a history here that I don’t understand and I should try to understand. And through that meeting, I got to know some people from Colombia and Venezuela.
So, I spent two summers traveling through Brazil, Colombia, and Venezuela. I was able to see firsthand the magnitude of the problem and what I consider an amazing disconnect between the progress that we were making scientifically with the lack of progress in terms of these people being cared for adequately.
A second thing that happened, after I finished a talk I gave in Brazil, there was an older HD patient from Brazil with his wife. He was in a wheelchair. His disease was pretty advanced, and he did not speak Spanish or English. His wife translated for him when he held my hand and he told me, “Please, please, I know it’s too late for me, but please help my daughter.” At that point, it really made me feel for the first time that the work that we were trying to do was really transgenerational. I might not be able to help many of the other people I would meet directly, but the work I was doing in the advocacy realm could help build a better future for future generations.
So those two things were really impactful for me and it kind of launched me into understanding better the patient perspective by visiting these communities. After I did, I decided I needed to do anything to help them, and that’s how Factor-H was born.
HDBuzz: What’s the story behind the name of Factor-H?
Nacho: I struggled a little bit with a name that could resonate in Spanish and in English. The word “factor” is the same in both languages, number one.
I started thinking about the fact that Huntington’s disease can become the dominant factor in people’s lives. It’s just all encompassing for everybody who is affected and their family members. And I wanted to create an organization where the factor “H” for Huntington’s brought us together, but slowly the H of Huntington’s will be replaced by the H of hope and the H of humanity. So that’s why I call it Factor-H, Huntington’s, Hope, and Humanity.
The idea is hopefully, through science and through our advocacy work, we can support those families so that they develop other factors in their lives that really bring them satisfaction, happiness, stability, and growth.
HDBuzz: What inspired you to start Factor-H, and what is the organization’s primary mission?
Nacho: I have to be honest, at the beginning it was like, “I have no idea what I’m getting myself into. I don’t know what to do. I just saw some horrible things and I want to help.”
So I started organizing parties in my house and collecting clothes and toys. Essentially Factor-H was a project between myself and the other co-founder, who is a clinical geneticist from Buenos Aires, Dr. Claudia Perandones, who now manages the Enroll-HD project in South America, Spain, and Portugal. The two of us decided we needed to do anything that we could think of, but it wasn’t meant to be an organization. It was meant as a project to try to help people. But the more I started going every year, or multiple times a year, people started joining the project. At some point a few years later, I said, “Okay, well, we need to formalize this.”
That’s when we created Factor-H as a nonprofit registered in the United States, six years after I started, in 2018. I think by then the mission was quite clear, which is that we’re using Huntington’s disease to help communities that sit at the interface of neurodegenerative genetic disorders and poverty or conditions of extreme vulnerability. That’s why we focus on the communities that we do, which are the largest clusters of HD families in the world, in South America. They all have very similar characteristics in terms of lack of access to education, to medical care, and suffering from extreme discrimination, and a lot of psychological issues with children.
We took a very holistic approach and we reframed Factor-H as a human rights-based organization, focused on Huntington’s disease, because that’s the disease we know best. Not just taking care of the health implications of having the disease, but rather a broader approach for community development, education, supporting children, supporting caregivers, and essentially filling in for the gaps in access to all kinds of support and care that these communities experience.
We decided to focus on four major pillars, or areas of work. The first one is health, then is youth, community development, and data collection and advocacy. For community development, that includes anything from humanitarian assistance to renovation of homes, to buying adequate bedding for people, to eventually things like adequate bathrooms and septic tanks. A lot of these communities are living with no infrastructure, so to speak, that we’re used to.
For data collection and advocacy, this included establishing our own internal databases where we capture all medical, social, economic, educational information for all the families, so we have maps with the location of every family member that we’ve identified. We know how many kids, what their ages are, what their educational level is. So that’s all included in that area, and that enables us to prioritize the work, but also to begin to influence local entities to support those families when they can. So in many ways we have become the representative voices from those communities, both internationally and locally. Under the advocacy umbrella, we also organize conferences in Latin America, like scientific and medical conferences and other types of educational activities.
Factor-H’s Work & Impact
HDBuzz: Some of what you’re describing are really quite basic things that you’re providing to people. Help us illustrate the level of poverty that we’re talking about and the difficult situations that these people are living in. Can you tell us: What is the typical situation of a family that’s living with Huntington’s disease in Venezuela? What kind of house are they living in? Do they work? Do they have income? What is their life like? Can you paint a picture of what that is like for these families?
Nacho: In Venezuela particularly, we’re working in two main communities. One is located very close to the city of Maracaibo, which is the capital of Zulia state and is the second largest city in the country. There is essentially a small municipality, called San Francisco, of about 4,000 people north of the city, where about 10% of the people will develop Huntington’s disease.
Almost 30 to 40% of all the families in that municipality have a history of HD. Now, we don’t have access to genetic testing in that town, but we can tell you based on the number of patients and the number of individuals at risk, because we’ve characterized every family member there.
The community of Barranquitas, which was very instrumental to the identification of the gene that causes HD, is one of the largest in the world. It’s about 6,000 to 7,000 people, more or less. And again, based on our accounts, anywhere between 10% and 20% of the population will be affected with HD. That community is extraordinarily poor. Overall, about 80 to 90% of all the families we have been supporting live either in poverty or extreme poverty by international standards.
The vast majority don’t have an education. They’re relatively large family structures—five, six, ten children. For many of them, if the mother is affected with HD, it’s fairly typical that they get abandoned by the father, so the kids grow up taking care of a mom and other sick relatives. Their houses, in many cases, lack electricity and running water. They are essentially tin-roofed huts with one room, with maybe a mattress on the floor or a few hammocks, that people have to share. We prioritize helping those extreme cases, but in these communities, the average family typically earns a very minimal income. So, it’s as extreme as you can think about.
HDBuzz: HD in and of itself brings intense, difficult challenges, but to imagine going through that in those conditions of extreme poverty presents incredibly unique challenges. Can you talk about some of those challenges that are specific for that population?
Nacho: The challenges really depend on where these families are living. We have different programs that are geared to Venezuela and Colombia, depending on what we think we can realistically do, and also to the level of support that they might have access to.
In Colombia, a lot of the families are dispersed in rural areas. So, basically, you are in the middle of a rural area with a house that is maybe a mile or two or three miles away from any other house. Then you have patients that have been kept in an isolated room without any type of social visits or interactions for years and years.
In Venezuela, because the communities are so affected, the patients are, in many cases, just walking around the streets and they are living close to family members. They might lack some resources that are available in Colombia, but they don’t lack social interactions. So, the way that the disease impacts quality of life really depends on these elements, which wasn’t clear to me until I started visiting a lot of these families where they may be in a room with no TV, with nothing to do for years at a time, with nobody coming to see them.
That’s part of the reason we established the social agents. They’re essentially social workers, but they’re not formally trained in social work—they go visit people regularly, they sit with them or they wash them. They also act as their representatives when problems arise or the people they visit lack medications or food.
In Venezuela, there are challenges everywhere. When I first went in 2013, there were very good neurology, psychiatry, HD specialists that were taking care of and visiting people. There was access to the genetic test. All of those professionals left the country. So, one of the biggest problems is trying to reconstruct basic neurological and medical services in a landscape where people are continuously leaving the country. We managed, I think, to build an infrastructure in Venezuela that now works and many people are being seen regularly, but it took us a while to figure out how to actually do it.
Access to potable water and adequate food is a big problem for HD patients and children. There’s a lot of parasitic infections because they don’t have septic systems, for example, in Barranquitas. In many cases, families don’t eat more than once a day and the meals are not very nutritious. So, just trying to get regular support on nutritional supplements and adequate food is a problem with the numbers of families that we are supporting. In Venezuela alone, it’s about 600 families with a history of Huntington’s disease that we’re trying to support. At the present moment, I think we have about 205 patients that are clearly symptomatic. It’s probably quite a few more, but we are not calling them HD cases because we don’t have genetic testing.
In Colombia, depending on where people live, we have different sets of problems. The advantage of Colombia is that the healthcare system is operative, even though it’s very challenging for HD families to navigate. I’ll give you an example of one of the programs that I’m really proud of. The Colombian government has included Huntington’s disease in their rare disorders’ legislation, which guarantees access to medications and support like wheelchairs, mattresses, diapers, etc.
The problem is that a lot of the families we represent are poorly educated—many of them don’t know how to read and write, and they certainly don’t understand the rights from a legal perspective or how to access those rights. So, one of the things that we’ve done is to initiate a legal assistance program, where we have a lawyer that works at Factor-H, and now we teamed up with another legal non-governmental organization, and we are aiming to legally support every Huntington’s family that needs help throughout the country so that they know they legally have access to these resources.
For example, there’s a disability legislation that applies to people with Huntington’s disease, but most people don’t know they have those rights that covers a basic income. So, we’ve been doing all the paperwork to ensure that those individuals that don’t have disability status can get it, and therefore we help the affected individual, and also we help their family economically.
If the insurance companies in Colombia do not prescribe medications or wheelchairs or diapers, we present a case to them. We’ve done about 40 or so cases in the last two years, and we’ve won all of them. Now from that point on, the family gets all of the medical assistance the government is obligated to provide. That would never happen in Venezuela, because there is no such system in place, but in Colombia it does. So, a lot of the things that we do are really very much connected with the needs and the context in which these families are living and in what country.
Research & Scientific Collaboration
HDBuzz: In the US, we largely think about HD as a scientific problem. Especially as researchers, often from our view a critical thing is research and getting the research out to the people. But for the areas Factor-H serves, it’s almost an entirely different problem.
Nacho: The way I always think about it is that there are two parallel paths. There’s the path of science and medicine, which is the ultimate solution. We all work in this space and we all know why it’s so important, but it’s very slow. We don’t know when it’s going to happen.
When it happens, how will these families get access to those medications? This is a big area for me in the health domain. But there’s another parallel path, which are the things that we can do today. That really opens up a world of possibilities, because as long as you make people feel good and supported, this can improve their quality of life. That’s the approach that we take with Factor-H as a parallel avenue from scientific work. I think both are needed.
HDBuzz: Can you tell us about how data collection ties in with your work with researchers and clinicians and other stakeholders within this space to try and advance your mission.
Nacho: The only thing we don’t do at Factor-H is research, in the way we understand it— meaning participating in a study monitoring sleep or asking them to give us blood, for example.
The reason is that in Venezuela and in Colombia, and to some extent in Peru, most of the time outside doctors would only go and visit these people to study them. They would come one time, they would tell them all the wonderful things they were doing, they would ask for blood samples or psychological tests or whatever, they leave, and they would publish their paper, and never return.
It took me a number of years to earn the trust of those communities, to get them to feel, “OK, you’re a scientist, but you’re not here because you want something from us. You’re here to help us.” So, from the beginning, we decided that we are collecting this data in order for us to understand and be able to serve them, but not to use this data for medical or scientific research.
HDBuzz: We were wondering about that. How do these families feel about their contributions to research that got us to where we are today, knowing that many advancements, like AMT-130 or brain surgery, may not be accessible to them?
Nacho: That’s part of the work that we hope to do. I’ve already started discussing things with some companies that if their therapies get approved, whether we could institute a free access program for people, especially in Venezuela, assuming that we could.
A gene therapy is not going to be easily accessible in Venezuela, for example, but an oral drug or even ASOs could be. There’s a lot of excellent neurology centers in Latin America. Venezuela is probably the most isolated place right now in terms of access to some of these novel therapies, but for spinal muscular atrophy, many children in Latin America are benefiting from these ASO injections.
I’m more optimistic that as a community, if there are therapies that are approved and we apply some positive pressure and discussions, the number of families is not so large that it makes this a feasible proposition. But certainly, one of my key goals for Factor-H is to mediate that therapies are made available to people there.
All the money raised by Factor-H goes to South America and all the people who are hired by the charity are in South America. They’re all local people. As much as we can, we try to hire social workers for the community, the caregivers that we train are local caregivers. We’re trying to invest as much as we can directly or through education or professional training to focus on local people, because they’re the ones that are going to tell us if something is working or not working.
HDBuzz: Are there any other big unmet medical or social needs that you haven’t mentioned in these underserved regions?
Nacho: Anything that has to do with education is a big problem, especially disease-related education, whether it is the implementation and education around genetic testing and family planning. It’s a big problem in South America in general, both for cultural, religious, and educational barriers.
Education of the local family members as to how to deal with psychiatric symptoms in HD is a big problem. You could have a child or adolescent with juvenile HD. They don’t know what it is. They don’t know how to handle it. So, reinforcing education at all levels of the disease is fundamentally important—that’s laypeople, medical professionals, you name it.
Even though they live with this disease for a generation after generation, there’s still a lot of stigma and really a lack of understanding of the disease and how to deal with the symptoms. The educational aspect that worries me a lot is the education of the kids. We’ve been investing in this for more than 10 years now, which is to create a community of kids who are educated about HD, who have a support network with other HD at risk kids. So that when someone starts having problems, they have somebody to go and talk to.
Public Awareness & Advocacy
HDBuzz: How does Factor-H work to raise awareness about HD in the broader global community?
Nacho: Every four years we organize these very large CHDI-like conferences in South America where we fly in all the world experts. This is not limited to research and clinical trials; we include topics such as occupational therapy, legal rights, and other topics seldom dealt with in scientific conferences. That’s really created a lot of momentum with the local professional communities, and has brought the patient community closer with the professionals working in HD.
We’re still working on ways to more efficiently connect with the worldwide HD community, to let them know about the situation and to know about the work that we do to try to get more support. Certainly we thank you for this article, as HDBuzz is widely read!
HDBuzz: What are some of the largest barriers for increasing the amazing work that Factor-H is doing? Are they primarily financial, or are there other factors?
Nacho: Well, financial always, but I think if more people knew about Factor-H and more people understand that if they give $20, 100% of that donation goes to South America to help somebody. That $20 helps sponsor a child in our programs.
99% of all the philanthropic donations go to HD research because people want a treatment, and that’s not what we do. We also work in relatively small communities, in very poor countries, with a very specific segment of the HD population that not everybody has an interest in. However, it is my desire to make sure that we get more exposure in the sense that more people at a minimum know that these communities exist and how they live. I think if we can all pull together, we can do a lot of things with a relatively small budget.
HDBuzz: What are some of the main misconceptions about HD that you encounter, specifically in the communities that you’re working with?
Nacho: It’s becoming less and less since we’ve been there, but the biggest misconception was that HD was a curse. That there’s a problem with your family and your entire family is being cursed for the rest of life.
In other cases, people who are not from HD families wonder whether the disease is contagious. That really affects a lot of children because they can’t maintain friendships in school the moment they start having symptoms or people know they come from an HD family.
A lot of young people, which I don’t think is different in South America from Europe or North America, but a lot of kids are ashamed of talking about the disease because they feel that maybe their girlfriends or boyfriends, or potential girlfriend or boyfriend, won’t want to date them because they come from an HD family. They fear about their future and feel very alone.
I think in many cases, the fact that it’s genetic and the fact that just because your mom has HD doesn’t mean that you for sure are going to get HD continues to be a misconception that we’re trying to change.
Challenges & Future Goals
HDBuzz: What are the biggest barriers Factor-H faces in its mission, whether logistical, financial, or political?
Nacho: I’m very proud of the infrastructure that we’ve set up. We have clear goals, we have a lot of projects, but we have little money to implement them. In many cases, I am still dissatisfied with the level of healthcare support that we can provide continuously for these family members, especially the people that live in rural areas. It’s very expensive to bring somebody to a clinic every few months, but that’s an aspect that we need to expand. If it was up to me, I would have an entire medical team with maybe a medical van that can facilitate going whenever we need.
The lack of access to genetic testing is a big problem in Venezuela, in my opinion, but it’s not something that we can tackle at this point for many reasons.
If money weren’t an issue, we would do daycare centers for patients and for family members—a place that is safe, that is well conditioned, where they can come and rest and be entertained and where we can organize caregiver support, psychology support, and all the things that we’re doing, but in a properly adequate facility. That would be true in Peru, it would be true in Colombia, and it would be true in Venezuela. All these communities really yearn for a place of their own where they can build community and feel welcome and well cared for.
HDBuzz: How can people outside of Latin America—researchers, advocates, and the general public—support Factor-H’s mission?
Nacho: There’s a lot of things that we can collectively do that don’t involve money, but involve a little bit of time, like working on generating information in a way that is suitable for children or for teenagers about the disease. If someone does a run, they could choose Factor-H as their charity. We’re trying to build an app for caregivers where things are explained in very simple manners, with culturally sensitive language. So, it would be great to have a person that wants to volunteer time to do some coding for app generation, as an example.
All of us that are working on Factor-H all came from the same perspective—we wanted to do something, but we had no idea what to do. If you’re interested in helping our mission, get in touch and we’ll see what we can do together.
Closing Thoughts
HDBuzz: How can Gratitude Day help HD families reflect on their own struggles while also recognizing the even greater challenges faced by those in poverty who have contributed so much to HD research?
Nacho: That’s exactly why we created Gratitude Day. It was Jimmy Pollard’s idea as a way of trying to help raise awareness about what we were trying to do. He came up with the idea of using the day of the publication of the paper that first detailed the genetic cause of HD as a day of gratitude to all the families and to celebrate the collaboration between families and scientists and clinicians.
I think that’s given Factor-H exposure, but it’s also quite beautiful to see—people posting pictures and sending us photographs from all over the world, from India to New Zealand, to Russia, to Turkey, South America, and every year it’s growing. It’s a beautiful way of feeling part of a bigger purpose or a bigger community than just your family and close ones. I think that really helps patients and family members to understand that they’re not alone.
One of the things that I’ve experienced from the beginning was that a lot of people contact me, and they may be in Guatemala or Ecuador or other places, and they really don’t know anybody with Huntington’s disease and they don’t know any professional who knows about the disease. At Factor-H, we’ve become a little bit of a reference for those people. So, in many ways, the more exposure, the more that people will know, the more that we will be able to help.
HDBuzz: Do you have any final messages for HD families around the world that you would like to share?
Nacho: Let’s finish it with Gratitude Day, rather than Factor-H. We came up with Gratitude Day because we wanted to make sure that the immense contributions, particularly from the Venezuelan families, to research and clinical development are not forgotten.
Those extend beyond the identification of the gene. Some of the rating scales, including the UHDRS, were first developed and tested in the field in Venezuela. The first scales that incorporate the psychiatric and cognitive tests, the same. The first evidence of the fact that we have modified genes were identified in Venezuela. The brain samples, the cell lines that are still used in research are from Venezuelans—there’s about 130 different cell lines that are still available that are from the Venezuelan project. So, their contributions were enormous to science.
The second aspect is, if you ask any of the people that went to Venezuela—from Nancy Wexler to Diana Rosas,William Yang,Leslie Thompson,Gill Bates—their careers were influenced tremendously because they went to Venezuela and they were able to interact with those families. So, the sense of community, the sense of purpose, the sense of mission is still reverberating. I just don’t want it to get lost. We’re all getting older and some of the people that went to Venezuela might soon retire. I think the younger generations shouldn’t forget about everything that the Venezuelans contributed and the fact that they’re still there. They need our help, just like we asked for their help when we as a scientific community went there initially.
There are many people with Huntington’s living in conditions that are extraordinarily difficult and they need to feel supported. We have grown into a really powerful community worldwide over the last 20 years, but it’s not really a worldwide community yet. We tend to focus too much on economically developed countries and forget that there are hundreds and thousands of families who are left out of that conversation and I think it’s up to us to reach out to them.
So, for Gratitude Day, I would say try to join us, try to understand why we’re doing what we’re doing, come and join the cause. It’s a wonderful journey and people should just reach out and see where things go from there. Just like I did the first time I went to South America.
To learn more about the inspiring work that Nacho and Factor-H are doing, visit their website. You can stay connected to their mission by giving them a follow on Facebook or Instagram. These heroes are making a profound difference in the lives of the most vulnerable HD families, by bringing hope, dignity, and essential support to those facing unimaginable challenges.
